Plant-derived cannabinoids as anticancer agents

Trends in Cancer- FORUM| VOLUME 8, ISSUE 5, P350-357, MAY 2022
2022
Eve M. O’Reilly, Joanne M. Cosgrave, William M. Gallagher, Antoinette S. Perry

Please use this link to access this publication.

Abstract

Substantial preclinical evidence demonstrates the antiproliferative, cytotoxic, and antimetastatic properties of plant-derived cannabinoids (phytocannabinoids) such as cannabidiol and tetrahydrocannabinol. The cumulative body of research into the intracellular mechanisms and phenotypic effects of these compounds supports a logical, judicious progression to large-scale phase II/III clinical trials in certain cancer types to truly assess the efficacy of phytocannabinoids as anticancer agents.

This library aims to empower you with knowledge but it does not replace the personalized advice and guidance a healthcare professional can provide. Before implementing any changes to your health regimen based on the contents of this library, we strongly advise you to consult with a qualified healthcare professional. Your doctor’s expertise is essential for interpreting how these insights may apply to your unique health circumstances.